Received May 20, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Y015100 | OT |
no adverse event; Inbound call from HCP regarding a T/E for VARIVAX and PROQUAD. See T/E case #02792544. HCP reported that only VARIVAX was administered to one patient. PROQUAD was not administered to anyone. No symptomatic events reported. HCP agrees to be correspond; This spontaneous report was received from a/an Nurse and refers to a(n) 3-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 15-Apr-2025, the patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), (lot #Y015100, expiration date: 06-Sep-2026) 0.5 mL administered by Unknown route. On 15-Apr-2025, the patient started therapy with sterile diluent (MERCK STERILE DILUENT), 0.5 mL administered by Unknown route (indication, expiration date, and lot # were not reported). The patient started therapy with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX), for the treatment of Prophylaxis. On 15-Apr-2025, the patient experienced Inbound call from HCP regarding a T/E for VARIVAX and PROQUAD. See T/E case #02792544. HCP reported that only VARIVAX was administered to one patient. PROQUAD was not administered to anyone. No symptomatic events reported. HCP agrees to be correspond. On an unknown date, the patient experienced no adverse event. At the reporting time, the outcome of Inbound call from HCP regarding a T/E for VARIVAX and PROQUAD. See T/E case #02792544. HCP reported that only VARIVAX was administered to one patient. PROQUAD was not administered to anyone. No symptomatic events reported. HCP agrees to be correspond and no adverse event was unknown. The action taken with Varicella Virus Vaccine Live (Oka-Merck) and sterile diluent was reported as not applicable.
Diluent